Accendra Health, Inc.

Accendra Health, Inc. (ACH) Stock Analysis

$0.313

-0.002 (-0.73%)At close

Loading chart…
High
0.330
Open
0.320
VWAP
0.31
Volume
4.24M
Mkt Cap
—
Low
0.273
Amount
1.30M
EV/EBITDA, TTM
9.90

Accendra Health, Inc., formerly Owens & Minor, Inc., is a provider of products, technology, and services for health beyond the hospital for millions of people each year. The Company connects patients, providers, and insurers, delivering solutions for people living with chronic, complex health conditions. It provides delivery of products, including disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers a range of products and services for in-home care and delivery across diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure devices, and patient support services). The Company also provides clinical and administrative support services and related products and supplies.

AI analysis of Accendra Health, Inc. (ACH)

Sell

Accendra Health Inc is not a good buy right now due to significant financial challenges and negative performance indicators. The current price is $0.428, with a staggering year-to-date change of -84.71%. The RSI is extremely low at 9.216, indicating oversold conditions, but this could suggest further declines rather than a rebound. The company has reported a net loss of $89.1 million in Q2 2026, and its gross margin has decreased to 38.22%, raising concerns about its profitability and operational efficiency. The main risk is the ongoing revenue decline, with a 10.1% drop in Q2 compared to the previous year, which could further impact investor confidence.

Valuation Metrics

The current forward P/E ratio for Accendra Health, Inc. (ACH) is 6.94, compared to its 5-year average forward P/E of 3.32.

Forward P/E

Strongly Overvalued
5Y Average P/E
3.32
Current P/E
6.94
Overvalued
4.44
Undervalued
2.19

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
10.89
Current EV/EBITDA
9.90
Overvalued
13.69
Undervalued
8.09

Forward P/S

Strongly Undervalued
5Y Average P/S
0.07
Current P/S
0.01
Overvalued
0.09
Undervalued
0.05

Whales holding ACH

C

Coliseum Capital Management, LLC

+ HoldingACH

-27.73%

3M Return

Events Timeline

2026-08-10 (ET)

17:00:00

Stocks Open Lower as Middle East Uncertainty Grows

12:30:00

Major Averages Mixed at Open Amid Middle East Uncertainty

07:00:00

Company Reports Q2 Revenue of $613.2M, Below Expectations

07:00:00

2026 Revenue Consensus at $2.57B, Adjusted EBITDA View Lowered to $300M-$320M

07:00:00

Accendra Health CEO Edward Pesicka to Retire by 2026

News

ACH FAQ — answered by Alphio AI

Accendra Health, Inc., formerly Owens & Minor, Inc., is a provider of products, technology, and services for health beyond the hospital for millions of people each year. The Company connects patients, providers, and insurers, delivering solutions for people living with chronic, complex health conditions. It provides delivery of products, including disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers a range of products and services for in-home care and delivery across diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure devices, and patient support services). The Company also provides clinical and administrative support services and related products and supplies. It operates in the Healthcare sector.

Accendra Health Inc is not a good buy right now due to significant financial challenges and negative performance indicators. The current price is $0.428, with a staggering year-to-date change of -84.71%. The RSI is extremely low at 9.216, indicating oversold conditions, but this could suggest further declines rather than a rebound. The company has reported a net loss of $89.1 million in Q2 2026, and its gross margin has decreased to 38.22%, raising concerns about its profitability and operational efficiency. The main risk is the ongoing revenue decline, with a 10.1% drop in Q2 compared to the previous year, which could further impact investor confidence.

Community

More ↗
kappashrike4 days ago

I analyzed the key levels for $STRK. 0.05964 is the prior low reconstruction zone and the upper edge of the consolidation platform. After breaking above it, bearish pressure failed and bulls began testing upside space. On the signal side, the latest price is 0.11426, already far from the entry zone, with strong short-term absorption and no clear signs of distribution. Return is +909.01%. On the operational side, 0.11 is the psychological and short-term support conversion level; holding above it favors bulls, while a break below 0.10 calls for watching for a pullback. The 10x position has unrealized profit; I am taking partial profits in batches and using a trailing stop, not letting a winning trade turn into a gamble. $OG #EthereumRisesOver71%InQ3 $ACH

Show more
SpotSquall4 days ago

My current long-term altcoin portfolio: $ACH (Alchemy Pay) $LTC (Litecoin) $ETC (Ethereum Classic) $LDO (Lido) $FET (ASI) $PLUME (Plume) $SYRUP (Maple Finance) $CFG (Centrifuge) $TKO (Tokocrypto) $GEOD (Geodnet) My short-term trading portfolio: $BONK $BB $GUN $SOLV $SKL Adjustment: I sold LUMIA, LINEA, AXL, ALPINE, JUV, MITO, and RVN from both my trading portfolio and long-term portfolio, and replaced them with CFG.

Show more
trendanchor9/25/2026

$ALGO $BCH $ACH A lot of crypto traders focus on finding the next big crypto opportunity, but having the right knowledge and guidance is what really helps you stay consistent. I have personally found Alyssa's approach to trading very different from the usual hype you see online. Following her signals made me my first 140,000, and it's only been a few months since I started following her approach. Her guidance has helped me become more confident with my decisions and less likely to trade emotionally whenever the market gets volatile. I'm still learning every day, but the difference in my mindset and overall approach to trading has been noticeable.

Show more
rektcitadel469/16/2026

$TWT is at 0.4984. Short-term support is the lower Bollinger Band at 0.4958; a break below that would bring the 0.49 round number into focus. The Fear & Greed Index is 51, neutral. BTC has no clear direction, altcoin rotation is weak, and TWT is down 3.45% over 24h on only 0.4M in volume. MA5 has crossed below MA20, RSI at 32.9 is near oversold, but the MACD histogram has turned positive, and the funding rate of +0.0050% shows longs are still paying. The bias is bearish; on a rebound to 0.5000–0.5030, consider a short with TP1 at 0.4958 (lower Bollinger Band), TP2 at 0.4900 (previous low support), and SL at 0.5080 (above MA20). Also watch: $ACH and $PENDLE are relatively resilient. (Personal view only, for reference, not investment advice. Futures risk is extremely high, please strictly control position size.) [Data] Pair: TWTUSDT Direction: Short Entry: 0.5000-0.5030 TP1: 0.4958 TP2: 0.4900 SL: 0.5080

Show more
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading